Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-3 Injection in Acute Ischemic Stroke Within 48 Hours
CTR20231033Phase 2Completed
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of loberamisal in ischemic stroke, sponsored by Nanjing NeuroDawn Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
loberamisal
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20231033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231033.